Vergelijking

Icatibant vs. Linaclotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

138614-30-9

851199-59-2

Molecuulmassa

1304.52 g/mol

1526.74 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Icatibant

Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Icatibant	Linaclotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Icatibant

Volledige vermelding →

Linaclotid

Volledige vermelding →

Frequently asked questions

What is the difference between Icatibant and Linaclotid?: Icatibant is classified as "Onderzoek (overig)", while Linaclotid is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Icatibant or Linaclotid?: The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Icatibant and Linaclotid in Germany and the United States?: Duitsland: Icatibant — Op recept, Linaclotid — Op recept. Verenigde Staten: Icatibant — Op recept, Linaclotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Icatibant

Linaclotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Icatibant and Linaclotid?

Icatibant is classified as "Onderzoek (overig)", while Linaclotid is classified as "Onderzoek (overig)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Icatibant or Linaclotid?

The highest available evidence level is "Humane RCT" for Icatibant and "Humane RCT" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Icatibant and Linaclotid in Germany and the United States?

Duitsland: Icatibant — Op recept, Linaclotid — Op recept. Verenigde Staten: Icatibant — Op recept, Linaclotid — Op recept. These are factual summaries with source and review date on the individual pages.